Genflow Biosciences PLC (LSE: GENF), a leading company in the field of longevity, has revealed plans to reorganize its primary board of directors and scientific advisory board (SAB) in order
Genflow Biosciences (LON:GENF) Research Agreement Signed with Magnitude Biosciences Limited
Genflow (LSE: GENF) is pleased to announce it has entered into a research agreement with Magnitude Biosciences Limited (“Magnitude”), a UK-based, specialist biotechnology research organisation that supports drug discovery and
Genflow Biosciences (LON:GENF) International patent application
Patent portfolio strengthened with international patent application under the Patent Cooperation Treaty
Genflow Biosciences Plc (LSE:GENF) Company Update
Genflow (LSE: GENF), a UK-based biotechnology company focused on longevity and the development of therapies to counteract the effects of ageing and diseases associated with advanced age, is pleased to
Genflow Biosciences (GENF.L) First Day of Dealings
Admission to the Official List
Braveheart Inv Group (BRH.L) Holding in Phasefocus increased and other matters
Braveheart (AIM: BRH), the fund management and strategic investment group, is pleased to announce that it has conditionally acquired 22,145 shares in Phasefocus Holdings Limited (“Phasefocus”) from Synergy Investments Limited